List of works - David Sheridan

A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms

scientific article published in Scientific Reports

Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

scientific article published on 25 January 2019

Acute myeloid leukaemia: an unusual cause of biliary strictures

scientific article published on 14 March 2019

Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin.

scientific article published on 8 April 2009

Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey

scientific article published on 28 April 2017

Depressive symptoms in chronic hepatitis C are associated with plasma apolipoprotein E deficiency

scientific article published on 12 March 2014

Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes

scientific article published on 28 January 2016

Exploration of potential mechanisms of hepatitis C virus resistance in exposed uninfected intravenous drug users.

scientific article published on 5 May 2017

FibroGENE: A gene-based model for staging liver fibrosis

scientific article published on 16 November 2015

Hepatitis C virus and atherosclerosis: A legacy after virologic cure?

scientific article published on 10 November 2016

Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs).

scientific article published on 05 September 2012

IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis

scientific article published on 10 April 2017

IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection

scientific article published on 24 April 2014

IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study

scientific article

Insulin resistance and low-density apolipoprotein B-associated lipoviral particles in hepatitis C virus genotype 1 infection.

scientific article published on 12 October 2010

Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease.

scientific article

Intravascular transfer contributes to postprandial increase in numbers of very-low-density hepatitis C virus particles.

scientific article

Iron deficiency anaemia in chronic inflammatory rheumatic diseases: low mean cell haemoglobin is a better marker than low mean cell volume.

scientific article published on May 2005

Lipid interactions influence hepatitis C virus susceptibility and resistance to infection

scientific article published on 28 July 2017

Lipids and HCV.

scientific article published on 31 October 2012

MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C.

scientific article published on 15 September 2016

Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection

scientific article published on 25 May 2016

Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy - a pilot randomised clinical trial

scientific article published on 14 October 2013

PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism.

scientific article published on 21 November 2014

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

scientific article

TLL1 rs17047200 Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C.

scientific article published on 6 October 2017

List of works by David Sheridan

A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms

Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

Acute myeloid leukaemia: an unusual cause of biliary strictures

Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin.

Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey

Depressive symptoms in chronic hepatitis C are associated with plasma apolipoprotein E deficiency

Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes

Exploration of potential mechanisms of hepatitis C virus resistance in exposed uninfected intravenous drug users.

FibroGENE: A gene-based model for staging liver fibrosis

Hepatitis C virus and atherosclerosis: A legacy after virologic cure?

Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs).

IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis

IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection

IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study

Insulin resistance and low-density apolipoprotein B-associated lipoviral particles in hepatitis C virus genotype 1 infection.

Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease.

Intravascular transfer contributes to postprandial increase in numbers of very-low-density hepatitis C virus particles.

Iron deficiency anaemia in chronic inflammatory rheumatic diseases: low mean cell haemoglobin is a better marker than low mean cell volume.

Lipid interactions influence hepatitis C virus susceptibility and resistance to infection

Lipids and HCV.

MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C.

Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection

Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy - a pilot randomised clinical trial

PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism.

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

TLL1 rs17047200 Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C.